Voriconazole treatment of invasive aspergillosis: Real-world versus health-economic model results

Clinical Drug Investigation

Volumn 28, Issue 8, 2008, Pages 509-521

  Van Campenhout, Hilde ^a   Marbaix, Sophie ^a   Derde, Marie Paule ^b   Annemans, Lieven ^c,d  

^a PFIZER INC   (United States)

^b Veeda Clinical Research   (United Kingdom)

^c GHENT UNIVERSITY   (Belgium)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Antifungals, therapeutic use; Aspergillosis; Cost of illness; Modelling; Resource use; Voriconazole, therapeutic use

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CHLORPHENIRAMINE; HYDROCORTISONE; ITRACONAZOLE; PARACETAMOL; PETHIDINE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BELGIUM; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION COST; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REIMBURSEMENT; THEORETICAL MODEL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BELGIUM; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 46749147213     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828080-00006     Document Type: Article

References (32)

1. Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006; 3: 35-40
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26 (4): 781-803
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66
4. E. R. Squibb and Sons Limited. Summary of product characteristics for Fungizone [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/ c/html/displaydoc.asp?.documentid=559 [Accessed 2006 Jun 1]
5. Maertens J, Theunissen K, Boogaerts M. Invasive aspergillosis: focus on new approaches and new therapeutic agents. Curr Med Chem Anti-Infect Agents 2002; 1: 65-79
6. Lewis JS, Graybill JR. Fungicidal versus fungistatic: what's in a word? Expert Opin Pharmacother 2008; 9: 927-35
7. Maertens J, Boogaerts M, The place for itraconazole in treatment. J Antimicrob Chemother 2005; 56 Suppl.1: i33-8
8. Maertens J, Raad I, Pettrikos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71
9. Pfizer Inc. Voriconazole summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc. asp?.documentid=10059 [Accessed 2008 Mar 1]
10. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2004; 2: 485-97
11. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 67: 269-98
12. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34 (5): 563-71
13. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15
14. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-25
15. Muijsers RB, Goa KL, Scott LJ. Voriconazole: in the treatment of invasive aspergillosis. Drugs 2002; 62: 2655-64
16. Peys F. The pharma sector and its financing in Belgium. Eur J Health Economics 2001; 2: 33-8
17. Marbaix S, Marciniak A, De Mees V, et al. Cost-effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium [abstract no. PIN 13]. Presented at the International Society for Pharmacoeconomics and Outcomes Research 6th European Congress; 9-11 Nov; Barcelona. Value Health 2003; 6; 750
18. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14
19. Wenzel R, Del Favoro A, Kibbler C, et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005; 55 (3): 352-61
20. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6 (1): 9-17
21. Black N. What observational studies can offer decision makers. Horm Res 1999; 51 Suppl. 1: 44-9
22. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-8
23. Mattei D, Mordini N, Lo-Nigro C, et al. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant 2002; 30: 967-70
24. Marbello L, Nosari A, Carrafiello G, et al. Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient. Haematologica 2003; 88: ECR05
25. Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003; 37 Suppl. 3: S188-224
26. Troke PF, Schwartz S, Ruhnke M, et al. Voriconazole (VRC) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis [abstract no. M-1755]. Abstr Intersci Conf Antimicrob Agents Chemother 2003; 43: 476
27. Aguado JM, Cisneros JM, on behalf of the Spanish voriconazole group of voriconazole study. Voriconazole for the treatment of drug-resistant fungal infections: experience from a compassionate-use programme in Spain [abstract no. 509]. Clin Microbiol Infect 2004; 10 Suppl. 3: 1788
28. Steinbach WJ, Benjamin DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-8
29. Vehreschild JJ, Bohme A, Reichert D, et al. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol 2008; 87: 126-31
30. Jansen J, Kern W, Cornely O, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006; 9: 12-23
31. Jansen JP, Meis JF, Blijlevens NM, et al. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005; 21: 1535-46
32. Mesrobian X, Loftus J, Roberts C, et al. Cost-effectiveness of voriconazole versus liposomal amphotericin B for invasive aspergillosis infection in the UK [abstract no. IN 3]. Value Health 2005; 8: A20